Pulmonary arterial hypertension Market is a rare and progressive disorder characterized by abnormally high blood pressure (hypertension) in the pulmonary artery. Further this is defined as a resting mean pulmonary artery pressure of 25 mm Hg or above. The condition is characterized by symptoms like shortness of breath, tiredness, chest pain, dizziness, fatigue, and swelling of the legs and ankles. Symptoms can develop slowly early and in severity among patients. Further high blood pressure in the pulmonary artery makes it difficult for the right ventricle to pump blood into the lungs. The growth of the market is due to increasing innovative products and launch. Besides increase in healthcare spending & adoption of treatment are the factors that drive the growth of the pulmonary arterial hypertension market
Pulmonary Arterial Hypertension Market Report Outlook
The key factor driving the growth of market is advancement of new technology. For instance in September 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson had announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for UPTRAVI (selexipag) as an injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults with WHO functional class (FC) II-III, who are currently prescribed oral UPTRAVI but are temporarily unable to take oral therapy. Besides growing burden of pulmonary arterial hypertension as the incidence and prevalence of PH in population-based has proven challenging, in part, because of the lack of specificity of diagnosis. Beside government and private support for the development of orphan drugs is propelling the growth of market.
COVID-19 Impact on Pulmonary Arterial Hypertension Market Report
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the pulmonary arterial hypertension market. In addition, complete analysis of changes on the pulmonary arterial hypertension market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. COVID-19 impact was moderate on the pulmonary arterial hypertension market as the pandemic had led to stop the major production and supply for months
Get Free Sample Research Copy for More Industry Insights:
https://www.axiommrc.com/request-for-sample/10435-pulmonary-arterial-hypertension-market-report
Pulmonary Arterial Hypertension Market Segmental Overview
The pulmonary arterial hypertension market is segmented based on by drug class, type, diagnosis, treatment, end users, sales channel and geography.
Pulmonary Arterial Hypertension Market by Drug Class
The pulmonary arterial hypertension has different drug class like endothelin receptor antagonists (eras), prostacyclin and prostacyclin analogs, sgc stimulators, pde-5 dipsticks. Endothelin receptor antagonists (eras) followed by prostacyclin and prostacyclin analogs accounted the significant market share in the pulmonary arterial hypertension market. The growth of endothelin receptor antagonists is due to advanced management of hypertension, as endothelin is one of the most potent vasoconstrictors and has significant increase in the sales of this drug. Besides prostacyclin and prostacyclin analogs have shown to improve symptoms and short-term survival in human patients with pulmonary hypertension thereby fueling the market demand and growth.
Pulmonary Arterial Hypertension Market by Type
The pulmonary arterial hypertension is available according to different type including idiopathic, heritable, associated. Idiopathic pulmonary arterial hypertension is major type of disease observed in pulmonary arterial hypertension market. It is high blood pressure in the arteries (blood vessels) of the lungs. The right side of the heart work harder to push blood to the lungs. The growth of segment is ultimately fueling the demand for pulmonary arterial hypertension market.
Pulmonary Arterial Hypertension Market by Diagnosis
The pulmonary arterial hypertension is diagnose by blood tests, chest x-ray, electrocardiogram (ecg), echocardiogram, right heart catheterization, polysomnogra. The blood test is mostly performed owing the easy available and detection. Besides electrocardiogram (ecg) provide supportive evidence to investigate symptoms of a possible heart problem, such as chest pain, palpitations (suddenly noticeable heartbeats), dizziness and shortness of breath. These signals are further recorded by a machine and are looked at by a doctor to diagnose the condition.
Pulmonary Arterial Hypertension Market by Treatment
The pulmonary arterial hypertension has various treatment including medication, surgery, therapy. Therapy is widely prefer for pulmonary arterial hypertension as preventing the disease from worsening. Further these are based on patient-specific factors and response. However, in worse cases surgery play a major important role in patients where medical therapy is unavailable or has been unsuccessful.
Pulmonary Arterial Hypertension Market by End User
The pulmonary arterial hypertension has end use in hospitals, specialty clinics, and home healthcare. Hospital is the major end user owing to advanced services like diagnosis tool and facilities provided for patient’s treatment. Also, rising inflow of patient in hospital is further fueling the demand for pulmonary arterial hypertension market. Moreover, hospital plays major in analysis, diagnosis and treatment of patients.
Pulmonary Arterial Hypertension Market by Sales Channel
The pulmonary arterial hypertension is distributed through following sales channel like hospital pharmacy, retail pharmacy, and online pharmacy. Hospital pharmacy leads in the pulmonary arterial hypertension owing to professionalize the functioning of the pharmaceutical services in hospitals thereby ensuring availability of the required medication at an affordable cost at the required time. Also, hospital pharmacy help the patients , medical staff, nurses and others involved in patient care on the use of drugs, possible side effects, toxicity, adverse effects, drug interactions etc. The hospital pharmacy has huge demand owing to presence in the hospital area. Whereas, online pharmacy provides accessibility to people in remote areas as well as urban areas further providing discounts, doorstep delivery within a short time, and validation of prescription.
Pulmonary Arterial Hypertension Market Key Players
The key players in pulmonary arterial hypertension market are Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co. Inc., Novartis International AG, Pfizer, Inc. and United Therapeutics Corporation among others.
Buy Now and Get More Discount:
https://www.axiommrc.com/buy_now/10435-pulmonary-arterial-hypertension-market-report
About Us
Axiom Market Research & Consulting™ is a full-service market research and data analytics company providing key market intelligence to global companies to take informed business decisions pertaining to their marketing strategy, investments, new product launches, market competition, consumer or end users, social media trends etc.
Axiom Market Research & Consulting™ offers market research services such as syndicated market research, custom market research, business consulting, and consumer/end user surveys. Under Business to Consumer (B2C) market research offerings, Axiom MRC assists its clients in finding quantitative information/preferences of its brands and services such as, awareness, usages, satisfaction, tracking, ethnicity etc. Axiom MRC offers data collection services through online surveys, social media, data processing and interpretation.
Axiom MRC with its experienced team of research and data analysts, has delivered more than 5000+ Market Research Projects, 3800+ Data Analytics Projects, 1200+ Business Support Projects and has a 800+ Global Client Base. Axiom Market Research & Consulting™ aims to become the preferred market research and data analytics company by providing key market intelligence solutions for client’s business growth.
Contact Us :
Axiom Market Research & Consulting™
3 Germay Dr. Ste 4 - 4666
Wilmington DE 19804
U.S.:- + 1 (845) 875-9786
U.K.:- + 44 (0) 20 3286 9707
Email: sales@axiommrc.com
Website: https://www.axiommrc.com/
Follow On
LinkedIn: https://www.linkedin.com/company/axiom-market-research-and-consulting/
Twitter: https://twitter.com/AxiommrcCom
